Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire by Zhong, Weimin et al.
Genome-wide Characterization of a Viral Cytotoxic T Lymphocyte
Epitope Repertoire*□S
Received for publication, July 10, 2003, and in revised form, August 1, 2003
Published, JBC Papers in Press, September 5, 2003, DOI 10.1074/jbc.M307417200
Weimin Zhong, Pedro A. Reche, Char-Chang Lai, Bruce Reinhold, and Ellis L. Reinherz‡
From the Laboratory of Immunobiology and Department of Medical Oncology, Dana-Farber Cancer Institute
and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115
A genome-wide search using major histocompatibility
complex (MHC) class I binding and proteosome cleavage
site algorithms identified 101 influenza A PR8 virus-
derived peptides as potential epitopes for CD8! T cell
recognition in the H-2b mouse. Cytokine-based flow cy-
tometry, ELISPOT, and cytotoxic T lymphocyte assays
reveal that 16 are recognized by CD8! T cells recovered
directly ex vivo from infected animals, accounting for
greater than 70% of CD8! T cells recruited to lung after
primary infection. Only six of the 22 highest affinity
MHC class I binding peptides comprise cytotoxic T lym-
phocyte epitopes. The remaining non-immunogenic pep-
tides have equivalent MHC affinity and MHC-peptide
complex half-lives, eliciting T cell responses when given
in adjuvant and with T cell receptor-ligand avidity com-
parable with their immunogenic counterparts. As re-
vealed by a novel high sensitivity nanospray tandem
mass spectrometry methodology, failure to process
those predicted epitopes may contribute significantly to
the absent response. These results have important im-
plications for rationale design of CD8! T cell vaccines.
Antigen-specific recognition of peptides bound to major his-
tocompatibility complex class I (MHCI)1 molecules is mediated
by CD8! T lymphocytes. The stretches of linear peptide se-
quence recognized by these T cells, referred to as T cell
epitopes, generally consist of 8–11 contiguous amino acids (1,
2). CD8! cytotoxic T lymphocyte (CTL) responses play a central
role in protective immunity against viral and intracellular bac-
terial infections (3–5). Therefore, identification of MHCI-bound
(i.e. “restricted”) T cell epitopes that can induce cellular immu-
nity is critical in the development of CD8! T cell-based
vaccines.
Of the many CTL epitopes potentially available in a viral
genome, antiviral CD8! T cell responses usually focus on only
one or two immunodominant peptides (6). Apparently, the
great majority of potential CTL epitopes are silent under phys-
iological conditions. The mechanisms for this phenomenon,
termed immunodominance, are poorly understood. Current ra-
tional design of CD8! T cell vaccines is mainly focused on the
induction of antiviral immunity by immunodominant CTL
epitopes, assuming that protective CD8! T cell immunity is
mediated by recognition of immunodominant CTL epitopes.
Such a vaccination regimen is indeed efficient in conferring
immune protection against a variety of viral infections in mu-
rine models (7–9). However, many viruses, especially RNA
viruses, evade immune clearance of CD8! T cell-mediated
mechanisms by mutating immunodominant CTL epitopes, as
observed in a number of persistent, as well as acute, viral
infections (10, 11).
To circumvent this escape mechanism, new vaccination
strategies that target conserved CTL epitope regions of viral
proteins are needed. Preliminary studies suggest that sub-
dominant CTL epitopes may represent attractive potential can-
didates to induce a broader degree of antiviral CD8! T cell
immunity. It has been shown that both subdominant and even
so-called “non-immunogenic” epitopes are capable of eliciting
strong CD8! T cell responses, if appropriately primed in vivo
(12, 13). Furthermore, several recent studies (14, 15) have
documented a partial immune protection against lethal viral
challenge following immunization with subdominant or non-
immunogenic CTL epitopes. Thus, these epitopes are capable of
participating in the effector function of cell-mediated antiviral
immune responses. However, selection of appropriate candi-
date peptides has been difficult, requiring comprehensive bio-
chemical and functional characterization of the natural CTL
epitope population of an infectious agent. Traditional strate-
gies for CTL epitope identification, such as overlapping peptide
synthesis and antigen screening using T cell hybridoma-based
immune recognition strategies, have limited power.
In the present study, we explore combined bioinformatic and
functional approaches to rapidly identify, from the genome of
an infectious agent, CD8! T cell peptide targets for CTL
epitope-based vaccine design using the PR8 strain of influenza
A virus as a model system. Initially, SYFPEITHI, a well estab-
lished computer algorithm for prediction of MHCI binding pep-
tides (16), was used to pre-select all possible peptides with
potential mouse Db and Kb binding capacities from the genome
of the influenza A virus. This method identified 148 potential
binders. A second new computer algorithm, Probabilistic Model
of Proteosomal Cleavage (PMPC), was then used to prospect
the likelihood of proteasomal cleavage of the SYFPEITHI-pre-
dicted Db and Kb binders. Of these, 101 peptides scored with a
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high likelihood to be proteolytically processed by eukaryotic
proteasomes. Detailed functional analysis of all potential CTL
epitopes revealed that 16 peptides, 10 of which have not been
identified previously, could be recognized by CD8! T cells re-
covered directly ex vivo from lungs of influenza A virus-infected
B6 mice. This number of naturally processed and in vivo pre-
sented viral CTL epitopes is considerably larger than previ-
ously thought. By investigating peptide binding interaction
with MHC molecules, T cell repertoire potential, and aspects of
viral protein processing, parameters influencing immune
epitope display and recognition are revealed.
EXPERIMENTAL PROCEDURES
CTL Epitope Prediction—All potential T cell epitopes encoded within
the influenza A virus (strain A/Puerto Rico/8/34; PR8) proteome were
predicted using the motif matrix-based algorithm SYFPEITHI (16)
(syfpeithi.bmi-heidelberg.com/scripts/MHCServer.dll/home.htm). In the
case of the Kb molecule, we chose a Kb-matrix specific for predicted
8-mers, given that most peptides that bind to Kb are of this length (17).
As Db binds both 9- and 10-mers (17), two Db-specific matrices were
used. We selected peptides that had a score of at least 51% of the
optimum using the relevant matrices. The number of the predicted Kb
and Db binders was 73 and 75, respectively, corresponding to 1.6% of all
possible peptides from the PR8 proteome (see Table I and Supplemental
Table S1).
The number of potential CTL epitopes was further restricted by
employing a PMPC, to predict whether a peptide C terminus is likely to
result from proteasomal cleavage. This new method for the prediction of
proteosome cleavage was developed using the SRILM statistical lan-
guage model toolkit (18) and will be described in detail.2 Accuracy of the
model is "90% as determined by using a set of 932 natural MHCI-
restricted peptides.
Synthetic Peptides—A panel of 148 peptides derived from influenza
PR8 virus was synthesized at New England Peptide, Inc., Fitchburg,
MA, by solid phase strategy using Fmoc (N-(9-fluorenyl)methoxycar-
bonyl) chemistry on a Gilson AMS 422 synthesizer (Middleton, WI).
HPLC analysis showed that the purity of the synthesized crude pep-
tides was 86–92%. All peptides had expected masses as confirmed by
mass spectrometry. The subscript numbers of each peptide indicate the
amino acid positions starting from the N terminus of the corresponding
PR8 protein. Crude peptides were used for initial peptide binding as-
says. Selected crude peptides were purified to #96% by reverse phase
HPLC for further experiments in this study.
MHCI-Peptide Binding and Dissociation Assays—Binding of individ-
ual synthetic peptides from PR8 virus to mouse H-2 Db and Kb mole-
cules was evaluated by measuring stabilization of expression of MHCI
molecules on the surface of the TAP-deficient mutant cell line RMA-S
using flow cytometric analysis with anti-Db (clone HB-27) and anti-Kb
(clone B24–8-3) mAb (19). SD50 (peptide concentration that stabilizes
50% of the maximal number of Db or Kb molecules) was calculated
(Abelbeck Software) from a non-linear regression of the data to the
hyperbolic equation, f $ fmax (P)/[SD50 ! (P)], where f is the mean
fluorescence acquired at different concentrations of a peptide, (P) is the
corresponding peptide concentrations tested, and fmax is the maximal
fluorescence induced by a peptide.
The dissociation rate between peptides and MHCI molecules was
determined using 1 "g/ml of GolgiPlug (containing monensin; BD Bio-
sciences) to block the transportation of newly synthesized MHCI mol-
ecules from endoplasmic reticulum (ER) to the surface of RMA-S cells
(20). A half-life measure (t1⁄2, the time required for 50% of the molecules
to decay) was used to compare the stability of different peptide/MHC
(pMHC) complexes.
Infection of Mice with Influenza Virus—The working stock of influ-
enza A/PR8/8/34 virus (PR8) used in this study was propagated and
produced from a PR8 seed virus kindly provided by Dr. David
Woodland, The Trudeau Institute, Saranac Lake, NY. The virus stock
was titered either directly by hemagglutinin assay to obtain its hemag-
glutinin unit (HAU) or in 10-day old embryonated chicken eggs to
determine its egg infectious dose (EID50).
Female C57BL/6 mice were purchased from Taconic (Albany, NY)
and housed under specific pathogen-free conditions at the animal core
facility of Dana-Farber Cancer Institute prior to infection with influ-
enza virus at 6–10 weeks of age. Mice were infected by inoculating 3000
EID50 of PR8 viral particles intranasally under anesthesia.
Intracellular IFN! Staining—Intracellular IFN! staining was per-
formed using the Cytofix/Cytoperm kit (BD Biosciences). Briefly, cells
from the bronchoalveolar lavage (BAL) were pooled from 12–15 mice on
day 10 after intranasal inoculation with PR8 virus. The cells were then
cultured for 6 h in the presence of 10 "g/ml PR8-derived synthetic
peptides and 1 "g/ml GolgiPlug. After culture, the responder cells were
washed and stained with rat anti-CD8 phycoerythrin conjugate, fol-
lowed by intracellular staining with rat anti-mouse IFN! fluorescein
isothiocyanate conjugate (BD Biosciences). Stained cells were acquired
on a BD Biosciences FACScan flow cytometer, and the data were ana-
lyzed using CellQuest software (BD Biosciences). The results are ex-
pressed as the percentage of CD8!IFN!! cells among total CD8! T
cells. BAL cells recovered from B6 mice infected with the virus for 10
days were stained with phycoerythrin-conjugated NP366–374/Db and
PA224–233/Db tetrameric reagents (The Trudeau Institute, Saranac
Lake, NY) and Cy-Chrome-conjugated anti-mouse CD8 # mAb (BD
Biosciences).
Single Cell ELISPOT Assay—Single cell IFN!-ELISPOT assay was
performed as described previously (21) except enriched CD8! T cells
from the lung of B6 mice infected with influenza PR8 virus for 10 days
were used as effectors. The results were expressed as the number of
antigen-specific spot-forming cells (SFC) per 1 % 104 CD8! T cells.
Assay resolution was determined by plating serially diluted PB1703–711-
specific CD8! CTL (see below) into the anti-mouse IFN! mAb-coated
ELISPOT plates. Upon activation with the corresponding peptide, a
linear relationship between the numbers of CD8! T cells plated and the
numbers of IFN!-producing spots was observed, with a 1/50,000 cells
responsive frequency (data not shown).
Generation of Short Term CD8! T Cell Lines—Mice were injected
subcutaneously with 50 "g of selected PR8-derived synthetic peptides
emulsified in 100 "l of complete Freund’s Adjuvant at the base of the
tail. 10 to 15 days following peptide immunization, 1.5 % 107 spleno-
cytes were cultured in T25 flasks in 10 ml of complete RPMI 1640
medium containing 0.5–1 "g/ml of the corresponding peptide. Cell cul-
tures were fed with 10 units/ml of recombinant human IL-2 (rIL-2; BD
Biosciences) on day 4. After an initial 7-day culture, viable cells were
selected by centrifugation through Lympholyte-M (Cedarlane, Hornby,
Ontario, Canada). 1.0 to 1.5 % 106 responder cells were then restimu-
lated weekly with 1.5 % 107 irradiated (3000 rads) splenocytes from
naı¨ve B6 mice in T25 flasks in the presence of 1 "g/ml of peptide and 10
units/ml of rIL-2. Lympholyte-enriched viable CD8! T cells were as-
sayed for cytotoxic activity in a 51Cr release assay on day 5 after three
to five rounds of restimulation in vitro.
51Cr Release Assay—To generate PR8-infected target cells, 2 % 106
mouse EL-4 lymphoma cells were washed and resuspended in 400 "l of
serum-free RPMI medium. The cells were then incubated with 10 HAU
(standard dose) of PR8 viral particles for 1 h at 37 °C. Alternatively, the
same number of EL-4 cells was infected with 200 HAU (high dose) of the
viral particles as indicated. Virally infected cells were transferred to
6-well plates containing 6 ml of complete RPMI medium per well and
incubated overnight. To generate peptide-pulsed target cells, 1–2 % 106
EL-4 cells were incubated with 20 "g/ml of individual influenza pep-
tides in 500 "l of complete RPMI medium for 1 h at 37 °C. Both
PR8-infected and peptide-pulsed EL-4 target cells were washed twice
and then labeled with 150 "l of 51Cr (Na51CrO4; PerkinElmer Life
Sciences) for 90 min at 37 °C. Unpulsed but 51Cr-labeled EL-4 cells were
used as control target cells. After washing three times, 1 % 104 target
cells were incubated with titrated concentrations of CD8! T effectors in
a final volume of 200 "l. 100 "l of supernatants were removed after 5 h
incubation for ! radiation counting.
Immunoprecipitation—RMA-S cells and EL-4 cells were either
pulsed with PR8 virus-derived synthetic peptides or infected with a
high dose of live PR8 viral particles as described above. Untreated
RMA-S cells and EL-4 cells were prepared as controls. The cells were
then lysed on ice for 10 min with immunoprecipitation assay buffer (20
mM Tris, pH 8.0, 1 mM EDTA, 100 mM NaCl) containing 1.5% CHAPS,
5 "g/ml leupeptin, and 25 "g/ml trypsin inhibitor (all from Sigma).
Peptide-bound Db molecules were immunoprecipitated by anti-Db mAb
(clone HB-27)-coated GammaBindPlus-Sepharose (Amersham Bio-
sciences), washed, covered with 50 "l of Tris buffer, and stored at
&80 °C before analysis by mass spectrometry.
Nanospray Tandem Mass Spectrometry on a Quadrapole Time of
Flight Spectrometer—The nanospray MS/MS used for identification of
PR8 virus-derived peptides from the virally infected EL-4 cells in the
present study is described in detail in the Supplemental Material. In brief,
the MS spectrum of a typical peptide extract is characterized by a set of
2 P. A. Reche, J.-P. Glutting, and E. L. Reinherz, manuscript in
preparation.
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peaks spaced by m/z corresponding to doubly charged ions with mass
deficits characteristic of peptides. An arbitrary m/z window (of unit reso-
lution) contains multiple parent ions, and an MS/MS spectrum of the
selectedm/zwindow contains a complexmixture of fragments. Prior to the
analysis of the extract, the MS/MS spectrum of the isolated target peptide
(a synthetic standard) is taken under defined (and optimized) collision
conditions, and this (reference) spectrum identifies the m/z windows that
contain the target peptide’s fragments and their relative intensity.
This statistical measure considers the m/z-dependent arrival of the
fragment ions as a Poisson process and formally calculates the proba-
bility that the MS/MS spectrum of the mixture would support N parent
ions that fragment with the m/z distribution contained in the reference
MS/MS spectrum. In brief, the reference MS/MS spectrum defines rel-
ative arrival rates for the fragmentation of the target peptide whereas
the experimental MS/MS spectrum records the net ion arrivals (counts)
for the measurement period (e.g. 20 min). The m/z values that have
positive intensity in the reference spectrum are interpreted in the
experimental spectrum as a sum of fragments from the target peptide
and chemical background. The probability P(N) that the experimental
spectrum supports at least N total events, distributed by the arrival
rates of the reference spectrum, is calculated by determining the ex-
pected number of each fragment event, nm/z, given N total events. If the
measured counts in the fragment m/z window are greater than the
expected nm/z, the associated probability is set to 1 (the unexpectedly
large counts are because of chemical background) whereas if the counts
are less than nm/z, the probability that this is a statistical fluctuation of
the Poisson process is calculated. The product of these probabilities over
all the fragment m/z values generates the decreasing function P(N).
The absolute magnitude of P(N) depends on experimental details
such as collection period, signal intensity, and chemical background. To
offset these variations the reference pattern is translated in m/z space
(denoted by x) before calculating P(N). The function P(N, x) is then a
surface that is displayed as a contour plot, and the signature of detect-
ing the target peptide becomes a prominent peak at zero translation, P(N,
0). A dominant peak at 0 translation means the MS/MS data of the
experiment support the intensity ratios of the reference spectrum primar-
ily at the reference m/z values. The Poisson measure is robust in the
presence of background overlaps with some of the target peptide’s MS/MS
peaks; the failure to measure enough counts in any of the expected
fragment windows rapidly decreases the probability of detection.
The MS/MS spectra of the synthetic peptides were measured under
collision conditions optimized for each peptide, creating a library of
reference MS/MS spectra. The pMHC complexes were isolated by im-
munoprecipitation from EL-4 total cell lysates as described above, and
peptides were extracted by mild acid treatment of the antibody-coated
beads. The peptide mixture was desalted by reverse phase and loaded
into a nanospray tip, and the MS/MS spectra of the m/z windows
corresponding to the reference spectra were measured under the pre-
established collision conditions. The Poisson measure of the reference
spectrum in the mixture MS/MS spectrum is then calculated as outlined
above.
RESULTS
Computational Prediction of All Potential H-2 Db- and Kb-
restricted CTL Epitopes Encoded by the Influenza PR8 Virus
Genome—Two important biological processes determine
whether a peptide segment within a native protein can be
naturally presented by a given MHCI molecule: 1) proteolytic
processing within the cell required to liberate the peptide (22);
and 2) binding of the excised peptide to the MHCI molecule
with sufficient affinity to create a stable epitope as a cell
surface pMHC for CTL recognition (23). We used a computer-
based algorithm, SYFPEITHI (16), to predict all potential Db
and Kb binding epitopes from the PR8 genome of influenza A
virus. Influenza A virus is a negatively stranded RNA virus
(24) whose genome consists of eight RNA segments that encode
11 protein products (Table I). To identify potential Db and Kb
binders encoded by the viral genome, the amino acid sequences
of each of the eleven viral proteins were searched by SYF-
PEITHI for all possible 8- and 9- or 10-mer peptide fragments
with binding potential for Kb and Db molecules, respectively.
Only peptides with an arbitrary binding score of #50% of the
maximal binding score were selected as “hits,” resulting in a
total of 148 peptides, including 73 potential Db and 75 potential
Kb binders (see Table I and Supplemental Table S1). These
peptides comprise 1.6% of the total potential numbers of influ-
enza A virus-encoded peptides. The predictions were further
verified by RANKPEP, our recently developed computer
algorithm (25).
The proteasome is the most critical protease system for gen-
erating the C-terminal end of a MHCI-restricted CTL epitope
(for review see Refs. 26 and 27). To assess whether the pre-
dicted Db and Kb binders would be processed by proteasomes,
we developed a computer-based algorithm, named PMPC, to
predict cleavage. As shown in Table I, 101 of 148 PR8-derived
peptides showed high likelihood to be cleaved by eukaryotic
proteasomes. Thus, by introducing a proteasomal cleavage mo-
tif-based algorithm, we reduced the potential numbers of CTL
epitopes by 32%, from 148 to 101.
Assuming these sequence algorithms are good predictors of
CTL epitopes, the known immunogenic Db- and Kb-restricted
CTL epitopes of the PR8 virus should be identified among the
predicted potential CTL epitopes. As shown in Supplemental
Table S1, with a single exception (Kb-restricted, subdominant
9-mer peptide PB1703–711), all four other known strong H-2
b
MHCI binders representing immunogenic CTL epitopes of the
PR8 virus in H-2b mice were anticipated. This list includes the
TABLE I
Db- and Kb-restricted CTL epitopes predicted from influenza PR8 virus
RNA segment
Protein product No. of potentialMHCl bindersa
No. of potentially
cleaved bindersb
Name Size ACNc Db Kb Db Kb
aa
1 PB2 759 P03428 8 7 6 6
2 PB1 757 P03431 13 13 7 11
3 PA 716 P03433 9 12 8 6
4 HA 566 P03452 10 12 9 11
5 NP 498 P03466 5 10 3 5
6 NA 454 P03468 10 7 8 4
7 M1 252 P03485 5 4 2 3
M2 97 P06821 1 2 1 1
8 NS1 230 P03496 4 2 1 1
NS2 121 P03508 3 2 1 3
Hypothetical protein (HP) 167 QQIVE1 5 4 2 2
Totals 73 75 48 53
a SYFPEITHI was used to predict the binding possibility of influenza PR8 virus-derived 8-, 9-, and 10-mer peptides to Db and Kb molecules.
b Potential Db and Kb binders predicted by SYFPEITHI were further screened by PMPC for their possible proteolytic cleavage by eukaryotic
proteasomes.
c SWISSPROT database accession number (ACN) of the viral proteins.
Class I MHC-based Immune Recognition of Influenza A 45137
 at UNIVERSIDAD COM
PLUTENSE DE M
ADRID on January 7, 2009 
www.jbc.org
Downloaded from
 
two identified immunodominant CTL epitopes (NP366–374 and
PA224–233) (28, 29), among the top 1.6% of the scoring peptides,
and correctly predicts that they and NS1133–140 would be pro-
teolytically cleaved. However, M1128–135 is not identified by
this proteosome prediction algorithm.
MHCI Binding Affinities of the Predicted Db- and Kb-associ-
ated Epitopes—The 148 candidate epitopes were synthesized,
and their binding affinity to Db and Kb molecules was deter-
mined by RMA-S assay. The SD50 (peptide concentration that
stabilizes 50% of the maximal number of Db or Kb molecules)
was calculated based upon the binding curve of individual
peptides. In this way, it was possible to quantitatively assess
Db and Kb binding affinity. Overall, 22 (10 Db- and 12 Kb-
restricted) peptides bound with high affinity (SD50 '500 nM)
whereas 92 peptides (42 Db- and 50 Kb-restricted) bound with
intermediate affinity (500 nM ' SD50 ' 15 "M). The remaining
34 peptides showed minimal (SD50 #15 "M) or no detectable
MHCI binding, even at the maximal peptide concentration
tested (100 "M). In summary, 114 of 148 (77%) SYFPEITHI-
predicted potential CTL epitopes from PR8 virus bound to
murine Db and Kb MHCI molecules with high or intermediate
affinity.
As expected from previous studies (30–32), five known im-
munogenic CTL epitopes of PR8 virus in the H-2b mouse could
be categorized as strong binders when tested by RMA-S assay
(Table II). Most notably, however, 17 additional strong MHCI
binders were identified in the present study, 10 of which have
not been reported previously. Together, the data demonstrate
that matrix-based algorithms can serve as powerful computa-
tional tools to predict with reasonable accuracy potential MHCI
binding epitopes from viral proteins.
Identification of Immunogenic PR8 Virus-derived CD8 T Cell
Epitopes by Intracellular IFN! Staining Assay—Previous stud-
ies (28, 30–32) have identified six CTL epitopes in the influ-
enza virus-infected H-2b mouse including the five strong bind-
ers noted in Table II and an intermediate strength Kb binder,
NS2114–121 (32). Thus, minimally six peptide epitopes are pro-
cessed and presented by professional APCs during influenza A
virus infection. To gain a genome-wide perspective on the nat-
ural CTL epitope repertoire in H-2b mice directed against the
PR8 virus, a high throughput intracellular IFN! staining flow
cytometry assay was used. The recognition of each of the pre-
dicted 148 potential CTL epitopes by CD8! T cells was assessed
from B6 mice 10 days after intranasal inoculation with PR8
virus. BAL cells harvested directly ex vivo from the lung of
infected animals were used as the CD8! T cell source, because
lung represents the prevalent anatomic site for CD8! T cell-
mediated immunity during the acute phase of a primary influ-
enza A virus infection (33). Furthermore, this time interval
following a primary viral challenge represents the peak of the
virus-specific CD8! T cell response in the murine model of
influenza A virus infection (34). As shown in Fig. 1A, compar-
ative experiments revealed that the numbers of IFN!-secreting
NP366–374- and PA224–233-specific CD8
! T cells correlated well
with those obtained by immunostaining with the corresponding
MHCI tetramers. Hence, intracellular IFN! staining is a reli-
able way to measure the frequency of viral-specific CD8! T
cells from freshly isolated materials. Representative results
obtained by intracellular IFN! assay are also shown in Fig. 1B
for NP366 –374, PA224 –233, PB1703–711, NS2114 –121, and
M1128–135. Note that the control background value of IFN!
staining CD8! T cells in the absence of peptides (no peptide)
was typically '1%.
As expected, CD8! T cells recovered by BAL from PR8-
infected animals responded dominantly to stimulation with
NP366–374 and PA224–233 peptides (see Fig. 1A and Table III).
The frequency of CD8! effector T cells specific for each of these
two CTL epitopes consistently accounted for about 13% of the
total CD8! T cells recruited into the lung. The other most
frequent CD8! population specificity was directed toward a
Kb-restricted epitope, PB1703–711. Originally reported as a sub-
dominant CTL epitope of PR8 virus in B6 mice (31), the fre-
TABLE II
Experimentally identified strong Db- and Kb binders and the stability of those MHCI-peptide complexes
Peptidea Sequence/MHC restriction Proteasomal cleavageb SD50
c t1/2
d T cell epitopee
nM h
NP54-62 RLIQNSLTI/Db ! 12.1 5.59 &
NP366-374 ASNENMETM/Db ! 15.2 5.17 !
PB1141-149 TALANTIEVF/Db ! 22.4 3.34 &
NA23-31 LQIGNIISI/Db & 36.9 5.24 &
NSI128-136 ILKANFSVI/Db & 43.8 3.87 &
HA332-340 TGLRNIPSI/Db & 54.9 2.56 &
PA224-233 SSLENFRAYV/Db ! 72.2 4.49 !
PBI140-148 TALANTIEV/Db & 98.5 6.73 &
NA45-53 TGICNQNII/Db ! 198.1 8.14 &
HA468-476 SQLKNNAKEI/Db ! 306.1 3.14 &
NA425-432 SSISFCGV/Kb ! 13.4 10.75 !
HA304-311 SSLPFQNI/Kb ! 39.7 4.85 &
PBI703-711 SSYRRPVGI/Kb Not considered 47.4 5.91 !
PBI652-659 KNMEYDAV/Kb ! 113.3 3.57 &
PA647-654 SLYASPQL/Kb ! 144.9 3.60 &
M1128-135 MGLIYNRM/Kb & 188.3 3.53 !
PB2227-234 VYIEVLHL/Kb ! 210.7 5.05 &
HA402-409 MNIQFTAV/Kb ! 167.7 5.95 &
PBI442-449 SSDDFALI/Kb ! 170.5 3.75 &
PB1464-471 RFYRTCKL/Kb ! 212.4 4.72 &
NS1133-140 FSVIFDRL/Kb ! 312.8 2.98 !
NP35-42 IGRFYIQM/Kb & 358.3 3.64 &
a Peptides in bold indicate the known immunogenic CD8! T cell epitopes.
b Proteasomal cleavage possibility predicted by PMPC algorithm. !, cleavage predicted; &, cleavage not predicted; Not considered, not among
the top 1.6% of the potential MHCI binders when examined by either SYFPEITHI or RANKPEP algorithm, because no Kb 9-mers were assessed.
c Peptide concentration that stabilize a half-maximal number of MHCI molecules, as determined by RMA-S assay. A peptide was arbitrarily
considered as a strong binder if its SD50 was lower than 500 nM in RMA-S assay. One representative result is shown from two independent
experiments with similar results.
d The time required for 50% of the MHCI molecules to be lost from the surface of RMA-S cells. t1/2 for Db and Kb molecules in the absence of
peptides was 1.50 and 2.10 h, respectively. One representative experiment out of two is shown.
e Identified by flow cytometry intracellular IFN! assay and/or ELISPOT.
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quency of CD8! T cells responding to this epitope was variable
in this study, ranging from 5.5 to 13.8% in three independent
measurements. In addition, three known minor epitopes
(NS2114–121, NS1133–140, and M1128–135) were detected in the
intracellular IFN! assay. Most importantly, 10 previously un-
recognized CTL epitopes were identified in this manner. The
numbers of IFN!-secreting CD8! T cells in response to stimu-
lation with these peptides were above background values in
virtually all independent experiments conducted (Table III). In
sum, CD8! T cells recovered by BAL during the peak of a
primary influenza virus infection responded to 16 of the 148
predicted CTL epitopes, with NP366–374, PA224–233, and
PB1703–711 specificities being most prominent.
Identification of Subdominant CD8 Epitopes within the PR8
Virus by Single Cell ELISPOT Assay—Although efficient for
screening large numbers of antigenic peptides, intracellular
IFN! staining assay has limited detection sensitivity (typically
"1%). For more precise quantitation, we used a single cell
ELISPOT assay that readily detects a responsive cell frequency
of 0.002%. The numbers of IFN!-producing spots induced by
the 13 peptides tested were significantly above background
(3-fold or higher) with the NS1133–140 responsive T cells being
the lowest ("50 SFC per 104) and PB2689–696 being the highest
(320 SFC/104) (Fig. 1C). These data establish the clear immu-
nogenicity of these epitopes in H-2b mice infected with the
influenza A virus PR8. In contrast, 16 other PR8 virus-derived
FIG. 1. Genome-wide identification of immunogenic CTL epitopes of the influenza PR8 virus in H-2b mice. B6 mice were inoculated
intranasally with PR8 virus. 10 days after infection, BAL cells were collected from the infected animals and examined either by specific tetramer
and intracellular IFN! staining (A and B) or single cell ELISPOT (C and D). A, comparison of BAL cells stained with either NP366–374/Db or
PA224–233/Db tetramer versus intracellular IFN! staining. The numbers in the upper right quadrants of the fluorescence-activated cell sorter dot
plots indicate the percentage of epitope-specific or IFN!! CD8! T cells among the total CD8! T cells. B, CD8 and intracellular IFN! staining of
T cells recovered directly ex vivo from lung airways of virus-infected B6 mice. Shown is single cell IFN!-ELISPOT assay of PR8 virus-derived
peptides that were either immunogenic in the intracellular IFN! staining assay (C) or “non-immunogenic” but manifest strong MHCI binding in
RMA-S assay (D). CD8! T cells enriched from the lung of B6 mice infected with PR8 virus for 10 days were incubated with irradiated splenocytes
in the presence of 10 "g/ml of indicated peptides and 10 units/ml of rIL-2 for 24 h. IFN!-positive dots in each well were detected by developing the
plates with biotinylated anti-mouse IFN! mAb followed by streptavidin-horseradish peroxidase and substrate. The results were expressed as the
number of antigen-specific SFC/1 % 104 CD8! T cells. A count was considered positive if it was three times higher than that of control wells (CD8!
T cells and APCs without peptides), as indicated by the dotted lines.
TABLE III
Identification of murine H-2 Db- and Kb-restricted immunogenic CTL epitopes of influenza PR8 virus by intracellular IFN! staining
Peptidea Sequence/MHC restriction MHC bindingb Proteasomal cleavagec
% of responding CD8! T cellsd
Exp. 1 Exp. 2 Exp. 3
NP366-374 ASNENMETM/Db !!! ! 14.8 12.5 10.9
PA224-233 SSLENFRAYV/Db !!! ! 13.2 14.0 7.3
HA475-482 KEIGNGCFEF/Db !! ! 0.5 3.2 1.5
NA181-189 SGPDNGAVAV/Db !! & 1.7 2.8 3.1
NA335-343 YRYGNGVWI/Db !! ! 1.3 1.7 2.9
PB1703-711 SSYRRPVGI/Kb !!! Not considered 5.5 13.8 10.0
PB1214-221 RSYLIRAL/Kb !! ! 2.2 3.9 2.7
PB2358-365 GYEEFTMV/Kb !! ! 2.2 3.3 1.2
NS2114-121 RTFSFQLI/Kb !! ! 2.1 2.6 3.9
HP43-50 GGLPFSLL/Kb !! ! 1.5 2.5 4.0
NSI133-140 FSVIFDRL/Kb !!! ! 2.1 0.7 3.9
PA238-245 NGYIEGKL/Kb !! ! 1.4 2.9 1.5
PA300-307 GIPLYDAI/Kb !! ! 1.7 2.9 1.1
PB2689-696 VLRGFLIL/Kb !! ! 1.1 1.2 3.2
NA425-432 SSISFCGV/Kb !!! ! 0.9 1.0 2.5
M1128-135 MGLIYNRM/Kb !!! & 0.0 2.6 2.1
a Peptides in bold indicate known immunogenic CD8! T cell epitopes.
b Db and Kb binding affinity determined by RMA-S assay. !!!, strong binder; !!, intermediate binder.
c Proteasomal cleavage prediction as described in Table II.
d Percentage of IFN!-secreting CD8! T cells among total CD8! T cells, as determined by intracellular IFN! staining of CD8! T cells from BAL
of influenza PR8 virus-infected B6 mice on day 10 after infection. A total of 148 synthetic peptides were examined. A staining was considered
positive, when the percentage of CD8!IFN!! was three times higher than that of the background staining (without peptides). Only peptides that
resulted in positive results in more than one of three independent experiments are listed. The background staining were 0.02, 0.72, and 0.15%,
respectively.
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strong Db and Kb binders did not induce IFN! above back-
ground, demonstrating their lack of immunogenicity in the
context of native viral proteins (Fig. 1D). Thus, 16 of the 22
strong MHCI binding peptides failed to elicit in vivo T cell
responses.
Stability of Db- and Kb-Peptide Complexes—MHC-peptide
complex stability has been reported to contribute to the immu-
nogenicity of human immunodeficiency virus- and Epstein-
Barr virus-derived CTL epitopes (20, 35). Therefore, we next
compared the stability of the MHCI-PR8 peptide complexes. As
shown in Table II, no direct correlation between stability of the
MHC-peptide complexes and their immunogenicity in vivo is
evident. Immunodominant NP366–374 and PA224–233, for exam-
ple, do not form the most stable Db-peptide complexes (5.17 and
4.49 h, respectively). Conversely, the non-immunogenic
NA45–53 formed the most stable D
b-peptide complex, with a
half-life of 8.14 h. Peptides NP54–62, NA23–31, PB1140–148,
PB2227–234, and HA402–409, although non-immunogenic in vivo,
formed MHCI-peptide complexes at least equally stable as
those formed with the three immunodominant CTL epitopes.
Although the half-lives of MHCI-peptide complexes formed
with four Db-restricted peptides (PB1141–149, NS1128–136,
HA332–340, and HA468–476) and six K
b-restricted peptides
(PB1652–659, PA647–654, M1128–135, PB1442–449, NS1133–140, and
NP35–42) were particularly short (an average t1⁄2 being only
about 3 h), it is unknown whether this contributes to their lack
of immunogenicity in vivo. Nonetheless, neither strength of
peptide binding to MHCI nor pMHCI complex half-life alone
predicts immunogenicity.
Ability of Strong MHC Binders to Induce CTL Responses in
Vivo—If the TCR repertoire of B6 mice lacks specificities capa-
ble of recognizing certain PR8-derived peptides, this may ex-
plain the non-immunogenicity of a fraction of the H-2b binding
viral products. Consequently, we investigated the ability of
strong MHCI binders to elicit a CTL response in vivo. Peptides
chosen for this analysis were those non-immunogenic after
infection with PR8 virus, even with the highly sensitive ELIS-
POT assay (see Table II and Fig. 1D). Mice were immunized
with the selected strong Db and Kb binding peptides. Cytotoxic
activity of splenic CD8! T cells from immunized animals was
then measured against peptide-pulsed target cells. Initial eval-
uation showed that 5 of 12 effector populations tested were able
to mediate weak lysis of the corresponding peptide-pulsed tar-
gets but not an irrelevant PR8 virus-derived peptide-pulsed
target (data not shown). The 12 populations were then stimu-
lated repeatedly in vitro with their respective peptides to ex-
pand the antigen-specific CD8! T cells. Over 90% of the en-
riched effectors were CD8! T cells after three-four rounds of
restimulation (data not shown). All 12 short term CTL lines
showed strong cytotoxic activity against peptide-pulsed targets
(Supplemental Table S2). These data clearly indicate that
CD8! T cell precursors capable of responding to otherwise
non-immunogenic potential CTL epitopes of influenza PR8 vi-
rus exist in the naı¨ve CD8! T cell repertoire of B6 mice.
Relative Avidity of CTL Lines to Peptide-pulsed Targets—
Although the above results exclude complete absence of T cells
in B6 mice directed at the non-immunogenic/high affinity H-2b
MHCI binders, it is possible that the avidity of those TCRs for
their respective pMHCI ligands is too low to trigger activation
and differentiation of CD8! T cells in vivo. To investigate the
notion of a “functional” rather than absolute T cell deficit, the
short term CTL lines described above were used to lyse targets
coated with various amounts of each respective peptide. The
viral peptide concentrations necessary to lyse 50% of target
cells (EC50) were used to probe the relative avidity of each of
the TCRs from different CTLs to their corresponding MHCI-
peptide ligands. Variation in EC50 values between individual
experiments was less than 25% (data not shown).
As shown in Fig. 2, the EC50 for the three CTL lines directed
at immunodominant peptides, NP366–374, PA224–233, and
PB1703–711, were 0.04 % 10
&9, 0.9 % 10&9, and 0.9 % 10&9 m,
respectively. Surprisingly, the TCR of the CTL line specific for
the “non-immunogenic” HA304–311 showed much greater avid-
ity (100–1,000-fold) to the corresponding MHCI-peptide ligand,
with a 0.0005 % 10&9 M EC50. Moreover, a second non-immu-
nogenic peptide, PB1652–659, stimulated its respective CTL line
in the picomolar EC50 range comparable with that of the three
immunodominant CTL epitopes. Conversely, the CTL line spe-
cific for the non-immunogenic HA332–340 showed the weakest
avidity to its corresponding Db-peptide-pulsed target with a
9.0 % 10&9 M EC50. The data clearly show that a relatively high
avidity TCR-pMHC ligand requirement per se is not the dom-
inant factor determining immunogenicity of a potential CTL
epitope nor is an absolute or relative functional absence of TCR
specificity the basis.
Processing and Presentation of PR8 Virus CTL Epitopes in
Vitro—Failure to detect an epitope-specific CD8! T cell popu-
lation also may be attributed to absent or inefficient natural
processing, resulting in lack of sufficient pMHC surface com-
plexes to induce a CTL response in vivo. We used virus-specific
CTL lines to probe the availability of otherwise non-immuno-
genic, strong Db and Kb binders of PR8 virus on the surface of
EL-4 cells following in vitro viral infection. A major advantage
of this in vitro system is the ability to control the parameters
influencing the copy numbers of the virus-derived peptides on
the surface of the infected target cells (22, 36, 37).
We first tested CTL-mediated lysis of EL-4 targets infected
with a standard dose of the PR8 virus in vitro (10 HAU/2 % 106
cells). Approximately 25% of EL-4 cells were infected by the
virus under this condition, as judged by immunostaining of the
HA viral glycoprotein with anti-HA mAb (kindly provided by
Dr. Jonathan W. Yewdell, NIAID, National Institute of Health;
data not shown). As shown in Fig. 3, lytic effect was readily
observed when NP366–374-, NS2114–121- , or PB1703–711-specific
CTL lines were used as effectors. In contrast, the CTL line
specific for the PA224–233 epitope was only weakly lytic for the
virus-infected target, although such CTL manifest strong cyto-
FIG. 2. Relative avidity of TCR-based immune recognition by
antigen-specific CTL lines. PR8 virus-specific CTL lines were gen-
erated as described under “Experimental Procedures” and used to lyse
EL-4 targets pulsed with titrated amounts of the indicated peptides.
Peptide concentrations required to achieve 50% of the maximal lysis of
the targets (EC50) were used to compare the relative avidity of each
functional set of pMHC-TCR interactions. One of two experiments is
shown.
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toxic activity against PA224–233 peptide-pulsed targets. Given
that synthetic PA224–233 peptide possesses a high D
b binding
affinity and can form a relatively stable complex with Db mol-
ecules (Table II), the observed weak lysis suggests that this
viral protein may be insufficiently processed and/or presented
by EL-4 cell line in vitro (see below). CTL lines specific for
another two known subdominant CTL epitopes (NS1133–140,
M1128–135) as well as those generated to the eight non-immu-
nogenic strong binders, were capable of lysing the correspond-
ing peptide-pulsed targets with strong lytic activity, but their
lytic effect on the virus-infected targets were minimal (see Fig.
3 and Supplemental Table S2).
We then increased the infecting in vitro viral dose to 200
HAU/2 % 106 cells. This measured the frequency of virally
infected EL-4 targets to 75%, as judged by expression of the HA
glycoprotein (data not shown). Importantly, when NS1133–140-
and M1128–135-specific CTL lines were tested against the heav-
ily infected EL-4 cells, a detectable and specific cytotoxicity was
observed (Fig. 3). In contrast, HA332–340- and PB1652–659-spe-
cific CTL lines showed no significant cytolysis against EL-4
cells infected at either viral multiplicity of infection (see Fig. 3
and Supplemental Table S2). These data strongly suggest that
immunogenic peptides are naturally processed during viral
infection but that the degree of viral infection may influence
processivity, thereby determining lysis susceptibility. On the
other hand, non-immunogenic peptides may be processed too
inefficiently to target infected cells for lysis but allow CTL to
lyse cells when pulsed with exogenous peptide.
Detection of a Limited Number of Presented Peptides by
Nanospray MS/MS—The finding that the PA224–233 epitope is
immunodominant in vivo (see Fig. 1B and Table III) but results
in weak lysis for virally infected targets (Fig. 3) suggests that
this epitope may be insufficiently processed and/or presented
by EL-4 cells. This may be true for other peptide epitopes of the
PR8 virus, as well. A direct measure of the peptide density
displayed on the surface of infected EL-4 cells by a physical
method would address this issue. Therefore, an approach based
on nanospray MS/MS of unfractionated or partially fraction-
ated mixtures using a quadrupole time of flight spectrometer
was developed. Compared with conventional capLC (38), nano-
spray of appropriately cleaned peptide mixtures will produce
higher counts per mole because of the lower flow rate ('20
nl/min) and the ability to optimize the static spray.
The MS/MS spectra of the synthetic peptides were measured
under collision conditions optimized for each peptide, creating
a library of reference MS/MS spectra. The peptide mixtures
purified from either peptide-pulsed or virally infected EL-4
cells were loaded into a nanospray tip, and the MS/MS spectra
of them/z windows corresponding to the reference spectra were
measured under the pre-established collision conditions. A sta-
tistical measure, e.g. Poisson process, is used to identify the
signature of the reference spectrum in the spectrum of the
mixture (see Supplemental Figs. S1–S11). Such a measure is
especially robust in the presence of background overlaps with
some of the target peptide’s MS/MS peaks. Fig. 4 offers the
results of such analysis. For example, PA224–233 is readily
detected at one copy per cell using a mixture of uninfected EL-4
cells and PA224–233 pulsed RMA-S cells as detailed in the Sup-
plemental Material (Fig. 4A). In uninfected EL-4 cells, no
PA224–233 peptide is detected (Fig. 4B) whereas in PR8-infected
EL-4 cells, the Poisson statistics reveal its presence although at
a level of 'one copy/cell (compare panel C with panel A). This
low level of processing explains why the PA224–233-specific CTL
weakly kills PR8-infected EL-4 cells but readily lyses the
PA224–233 peptide-pulsed targets. The copy number of the latter
is orders of magnitude greater than present in the infected
sample (see Supplemental Material). In contrast, whereas
HA332–340 is also detectable by mix-in analysis at 10 HA332–340
copies per cell (Fig. 4D), this peptide is not observed in the
virally infected EL-4 cells (Fig. 4F) and yields a pattern indis-
tinguishable from uninfected EL-4 cells (Fig. 4E). In addition
PB1140–148 could also be detected at 10 copies per cell in the
mix-in analysis but not in the virally infected EL-4 cells (Sup-
plemental Figs. S9–S11).
FIG. 3. Endogenously processed and presented CTL epitopes of influenza PR8 virus. PR8 virus-specific epitopes that are processed and
presented on the surface of EL-4 targets after infection with a standard dose of the viral particles (10 HAU/2 % 106 cells) were detected by 51Cr
release assay using the corresponding CTL lines as effectors. NS1133–140- and M1122–135-specific CTL lines were further tested against EL-4 targets
infected with a high dose of the viral particles (200 HAU/2% 106 cells), as shown in the labeled panels on the right. The symbols used are as follows:
filled circles, PR8 virus-infected EL-4 targets; open circles; EL-4 targets without PR8 infection; filled triangles, peptide-pulsed EL-4 targets; open
triangles, EL-4 targets without peptide pulsing.
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DISCUSSION
MHCI-restricted antigenic peptides are derived from cytoso-
lic precursor proteins. After intracellular protein degradation,
mainly by proteasomes, the resulting peptides are translocated
to ER by TAP (transporters associated with antigen process-
ing), where they bind to newly synthesized empty MHCI mol-
ecules in a MHC allele-specific manner (39). pMHC complexes
are transported to the cell surface of professional APC for
recognition by CD8! CTLs via their TCRs. Proteasome cleav-
age, TAP transport, and MHC binding represent three key
processing events in generating immunologically relevant CTL
epitopes (27). Within the ER, peptides may be further trimmed
by ERAAP, an aminopeptidase associated with antigen
processing (40).
We used computer-based algorithms to rapidly search for all
potential CTL epitopes from the genome of influenza PR8 vi-
FIG. 4. Detection of viral peptide by nanospray MS/MS. A, PA224–233 detected in a mixture of peptide-loaded RMA-S and non-loaded EL-4
cells at a total concentration of one PA224–233 copy/cell. B, no PA224 signal in uninfected EL-4 cells. C, PA224–233 signal associated with infected EL-4
cells. D, HA332–340 detected in a mixture of RMA-S and EL-4 cells at a total concentration of 10 HA332–340 copies/cell as described. E, no HA332–340
signal in uninfected EL-4 cells. F, no HA332–340 signal in infected EL-4 cells. The plots show a single contour of a surface in which probability is
plotted as a function of m/z shift (x) and event number (y) (see Supplemental Material).
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rus. SYFPEITHI identified 148 peptide sequences with poten-
tial mouse Db and Kb binding capacities among the eleven
proteins encoded by the virus. Five of six known PR8 CTL
epitopes in H-2b mice were included among the top 1.6% of
potential CTL epitopes. The prediction results could be further
verified by the RANKPEP algorithm; "80% of the predicted
MHCI binders were identical in both algorithms. When exper-
imentally tested for their MHCI binding abilities by RMA-S
assay, 114 of 148 peptides (77%) were able to bind to mouse Db
and Kb molecules, although with a substantial range of binding
affinity. We infer that the 148 potential Db and Kb binders
originally predicted by SYFPEITHI algorithm may contain the
majority of the natural CTL epitopes of the virus.
The SYFPEITHI algorithm predicts potential MHCI binders
using a motif matrix (16). For pathogens with large genomes,
such as smallpox virus ("200 open reading frames) and
Chlamydia trachomatis (894 protein-coding genes), the list of
candidate peptides will be too long to be pursued practically.
Therefore, additional selection criteria are needed for CTL
epitope prediction. Comprehensive analysis of proteasome-di-
gested peptide products from unmodified model proteins has
generated abundant experimental data on cleavage specifici-
ties of proteasomes (41, 42), making it possible to extract pro-
teasomal cleavage motifs (e.g. preferred sequence patterns
around cleavage sites) for automated prediction (43). We devel-
oped a method based on a probabilist model to predict proteo-
some cleavage (PMPC), bypassing tedious experimental diges-
tion and biochemical analyses. When the 11 PR8 virus-coding
proteins were run on the proteasome program, 101 potential
MHC binders (67%) revealed a high processing probability
(Table I). Given this large number of proteins, experimental
data cannot be obtained to assess the predictive accuracy of
this algorithm. However, that 13 of 16 immunogenic CTL
epitopes identified could be anticipated among the peptide list
of potential proteasomal cleavage (Table III) suggests that our
PMPC algorithm may have substantial predictive power. The
combination of MHCI binding algorithms with proteasomal
cleavage programs represent a powerful search engine for ro-
bust, automated prediction of CTL epitopes from infectious
genomes.
We first used a high throughput intracellular IFN! assay to
screen the 148 potential T cell epitopes for CD8! CTLs recov-
ered directly ex vivo from the lung of PR8 virus-infected B6
mice. Lung represents the inflammatory site harboring the
highest frequency of virus-specific CD8! T cells during an
acute infection with influenza virus (33). As expected, three
known immunogenic CTL epitopes, e.g. NP366–374, PA224–233,
and PB1703–711, were readily detected by this assay (see Fig. 1
and Table III). Most importantly, 13 other PR8 virus-derived
peptides were found to be immunogenic in virally infected B6
mice, 10 of which have not been identified previously (Table
III). The immunogenicity of these minor CTL epitopes in vivo
was further confirmed by single cell ELISPOT assay (Fig. 1C)
and collectively establishes that over 70% of CD8! T cells
recruited into the lungs of the mice during a primary influenza
A infection are virus-specific. The remaining 30% of the CD8!
T cells may reflect bystander activation with specificity for
other antigens or include a subset of CD8! T cells with speci-
ficity for influenza A epitopes distinct from those predicted.
Nonetheless, the data suggest that combined use of SYF-
PEITHI and PMPC predicts the majority of the naturally ex-
isting CTL epitopes of the influenza PR8 virus.
These 16 CTL epitopes are directed at 10 of the 11 PR8 viral
proteins, products of both early and late genes of the virus (44).
The only viral gene that fails to encode demonstrable epitopes
is the M2 matrix protein, the smallest of the viral proteins,
predicted to harbor only one possible Kb and one Db binding
peptide. Thus, in contrast to previous observations (28, 29, 31)
showing that CD8! T cells target primarily internal proteins of
influenza A virus in H-2b mice, the data presented here clearly
establish that T cell recognition includes coverage of the vast
majority of viral products.
Three of the 16 Db- and Kb-restricted peptide epitopes
(NP366–374, PA224–233, and PB1703–711) collectively account for
the majority of CD8! antigen-specific CTLs from B6 mice in-
fected with PR8 virus (Table III). The precise molecular basis of
this immunodominance is not yet clear. Presentation may be a
key factor in determining immunogenicity of an epitope and
involves the availability of peptides for assembly into pMHC in
the ER and their MHCI binding affinities (22, 37). In the
present study, we found that 101 of 148 potential CTL epitopes
could theoretically be processed by proteasomes. However, the
majority were intermediate or weak MHCI binders, as deter-
mined experimentally by RMA-S assay. Therefore, it is most
likely that these peptides may not productively bind to MHCI
molecules in the ER, especially in an environment that places
them in competition with strong MHCI binders. The “subdomi-
nance” of the 10 newly identified CTL epitopes may be ex-
plained by their intermediate MHCI binding affinity (Table
III).
Seventeen PR8 virus-related peptides were able to bind to
MHCI molecules at least as strongly as the three immunodomi-
nant CTL epitopes (Table II), yet they are non-immunogenic
(Fig. 1D). Analysis of off-rates revealed that 11 of 17 strong
MHC binders dissociated very rapidly from the MHCI mole-
cules (Table II). Furthermore, failure to detect cytolysis of
heavily infected target cells by the two non-immunogenic,
strong Kb binders tested, e.g. PA647–654 and PB1652–659, implies
either a T cell repertoire limitation (see below) or that these
peptides are not presented or in too low numbers to induce a
detectable CD8! T cell response in vivo, as suggested by ELIS-
POT analysis (Fig. 1D). This latter assumption is further sup-
ported by the absence of HA332–340 peptide epitopes on the
surface of EL-4 cells infected with PR8 in vitro using physical
measurements (Fig. 4). Because the in vitro system may not
reflect the physiologic conditions, it is crucial to assess antigen
processing and presentation in vivo. The nanospray MS/MS
method herein can detect as low as one copy number of peptide
per cell using 2 % 107 cells, an "100-fold greater sensitivity
(Fig. 4) compared with the conventional HPLC-MS analysis
requirement. This new MS methodology should allow us to
dissect antigen processing and presentation in various APC
compartments from ex vivo infectious materials in the future.
The repertoire of responding CTL is another important pa-
rameter determining epitope immunogenicity. The observation
that 10 non-immunogenic, strong Db and Kb binders were able
to induce epitope-specific CTL in vivo when given as peptide
immunogens in complete Freund’s Adjuvant (Supplemental
Table S2) suggests that relevant CTL precursors are present in
the pre-immune CD8! T cell repertoire of B6 mice. The lack of
responsiveness to the strong Db and Kb binders does not appear
to be because of low avidity between responding TCRs and
pMHC ligands, as peptide titration data reveal that the avid-
ities of the respective CTL lines are essentially similar to those
of immunodominant CTLs (Fig. 3). Hence, there seems to be no
obvious functional defect (i.e. holes) in the responding CD8!
CTL repertoire for the silent strong Db and Kb binders of the
PR8 virus. The absence of CD8 T cell responses to those strong
binders is probably linked to poor antigen processing during
influenza A infection in vivo.
Although anti-viral CD8! T cells may recognize only several
immunodominant CTL epitopes, our data show that the num-
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ber of endogenously processed and presented epitopes is larger
than thought previously. The strength of immune response to
these minor CTL epitopes appears to be regulated by several
factors including MHCI binding affinity, stability of pMHCI,
and the level of epitope presentation. The phenomenon of im-
munodominance cannot be explained by any single variable.
Because multiple viral proteins can serve as potential vaccine
candidates for induction of virus-specific CTL, it is tempting to
speculate that a CD8! T cell vaccine consisting of multiple
minor viral CTL epitopes may induce broad immunity in vivo.
This may be of particular importance in situations where gen-
eration of viral variants during infection represents a major
obstacle for immunodominant CTL epitope-mediated viral
clearance.
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